Have a feature idea you'd love to see implemented?
Let us know!
DMAC DiaMedica Therapeutics Inc
Price (delayed)
$4.18
Market cap
$178.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
$174.97M
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.
Highlights
DMAC's debt is down by 13% year-on-year and by 6% since the previous quarter
The company's EPS rose by 10% YoY but it fell by 6% QoQ
The quick ratio has contracted by 46% YoY and by 33% from the previous quarter
The net income has contracted by 20% YoY and by 8% from the previous quarter
Key stats
What are the main financial stats of DMAC
Market
Valuations
Earnings
Shares outstanding
42.76M
Market cap
$178.74M
Enterprise value
$174.97M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.73
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$21.45M
EBITDA
-$21.34M
Free cash flow
-$19.48M
Per share
Balance sheet
Liquidity
EPS
-$0.56
Free cash flow per share
-$0.46
Book value per share
$1.12
Revenue per share
$0
TBVPS
$1.23
Total assets
$52.52M
Total liabilities
$4.56M
Debt
$365,000
Equity
$47.96M
Working capital
$46.47M
Debt to equity
0.01
Current ratio
11.81
Quick ratio
11.75
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.4%
Return on equity
-43.3%
Return on invested capital
-48.6%
Return on capital employed
-44.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DMAC stock price
How has the DiaMedica Therapeutics stock price performed over time
Intraday
3.98%
1 week
1.46%
1 month
-2.56%
1 year
67.87%
YTD
47.18%
QTD
-0.24%
Financial performance
How have DiaMedica Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.11M
Net income
-$21.5M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 24% YoY and by 8% from the previous quarter
The net income has contracted by 20% YoY and by 8% from the previous quarter
Growth
What is DiaMedica Therapeutics's growth rate over time
Valuation
What is DiaMedica Therapeutics stock price valuation
P/E
N/A
P/B
3.73
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 10% YoY but it fell by 6% QoQ
The stock's price to book (P/B) is 43% more than its last 4 quarters average of 2.6 and 13% more than its 5-year quarterly average of 3.3
DiaMedica Therapeutics's equity has decreased by 14% YoY and by 10% from the previous quarter
Efficiency
How efficient is DiaMedica Therapeutics business performance
DiaMedica Therapeutics's return on invested capital has decreased by 14% QoQ and by 10% YoY
DiaMedica Therapeutics's return on equity has decreased by 12% QoQ and by 5% YoY
The return on assets has declined by 11% since the previous quarter and by 4.1% year-on-year
Dividends
What is DMAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DMAC.
Financial health
How did DiaMedica Therapeutics financials performed over time
DiaMedica Therapeutics's total liabilities has soared by 82% YoY and by 35% from the previous quarter
The quick ratio has contracted by 46% YoY and by 33% from the previous quarter
DMAC's debt is 99% smaller than its equity
DiaMedica Therapeutics's equity has decreased by 14% YoY and by 10% from the previous quarter
DMAC's debt is down by 13% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.